News

Search For News


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

1. The UK's 2017 Spring Budget - Potential Impact on the UK Biotech Indus

The UK's 2017 Spring Budget - Potential Impact on the UK Biotech Industry16/03/2017 Oxford, UK - The Spring Budget delivered by the Chancellor on 8 March 2017 continues to hit the headlines.  What is its potential impact on the UK biotech industry?Contributed by Mike Shearan, Senior Manager, James Cowper Kreston (and OBN Investment & Tax Special Interest Group (ITSIG))We set out briefly below some announcements from the Budget which affect the biotech industry in longer-t


2. Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in P

Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients with DMD27/03/2017SUMMIT TO EXTEND ONGOING PhaseOut DMD CLINICAL TRIAL OF EZUTROMID IN PATIENTS WITH DMDDecision follows interim safety review by PhaseOut DMD's independent Data Monitoring CommitteeOxford, UK, 27 March 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficileinfecti


3. Alimera Sciences Signs Agreement for Exclusive Distributor of Iluvien

Alimera Sciences Signs Agreement for Exclusive Distributor of Iluvien in Spain13/03/2017Brill Pharma S.L. to also serve as agent in price negotiations with the Spanish Ministry of HealthAlimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Alimera Sciences Limited, its European subsidiary based in London, has signed an exclusive agreement with Br


4. AstraZeneca and Circassia Enter Strategic Collaboration in Respiratory

AstraZeneca and Circassia Enter Strategic Collaboration in Respiratory Disease17/03/2017> Circassia will lead promotion of Tudorza and prepare for potential launch of Duaklir in the US> Strategic collaboration further sharpens AstraZeneca’s respiratory focus on Symbicort, Bevespi Aerosphere, benralizumab and other development programmesAstraZeneca today announced it has entered a strategic collaboration with Circassia Pharmaceuticals plc, a respiratory biopharmaceutical company, for


5. Adaptimmune Therapeutics plc Proposes Public Offering of American Depo

Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares21/03/2017Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Adapt



Page 22 of 30 ( 148 results in total )
© Catalyst Innovation Portal 2019